Year Founded
2018
Ownership
Public
Therapeutic Areas
HematologyOncologyNeurology
Stage
Phase 1
Modalities
Small molecule

Cullgen General Information

Two compounds in clinical trials: CG001419 (Phase 1 for pain) and CG009301 (Phase 1 for hematological malignancies)

Contact Information

Website
Primary Industry
Biotech
Corporate Office
San Diego, California
United States

Drug Pipeline

CG001419
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Cullgen's pipeline data

Book a demo

Key Partnerships

Astellas

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Cullgen Funding

Deal TypeDateAmountStatusStage
Later Stage VCMay 8, 2023$35.0MCompletedPhase 1
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Cullgen's complete valuation and funding history, request access »

Cullgen Investors

AstraZeneca-CICC Venture Capital Partnership
Investor Type: Venture Capital
Holding: Minority
GNI Group Ltd.
Investor Type: Venture Capital
Holding: Minority
Sincere Capital
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »